The focus of the EBOMAN project was on accelerating the development and manufacturing of the two-dose Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN®-Filo), in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Ebola vaccines can only be manufactured in facilities with an appropriate biosafety rating. Relatively few manufacturers have the biosafety rating required for the manufacture of Ebola vaccines, and this has created challenges in the production of vaccine candidates.

The EBOMAN project established a platform capable of rapidly producing sufficient quantities of the vaccine, while adhering to stringent quality and safety requirements. In the short term, this ensured the delivery of sufficient quantities of the Ad26.ZEBOV and MVA-BN®-Filo vaccine regimen to support the EBOVAC projects to perform the clinical trials. The project will also help prepare for future vaccination campaigns through creating additional vaccine production capacity to allow for the rapid preparation of large quantities of vaccines.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2024 Ebovac | Terms and Conditions | WordPress development by Toast.